» Articles » PMID: 37636564

Neutrophil Extracellular Traps-related Signature Predicts the Prognosis and Immune Infiltration in Gastric Cancer

Overview
Specialty General Medicine
Date 2023 Aug 28
PMID 37636564
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Gastric cancer (GC) is the fifth most prevalent cancer globally, with the third highest case fatality rate. Neutrophil extracellular traps (NETs) are a reticulated structure of DNA, histones, and antimicrobial peptides produced by active neutrophils that trap pathogens. Even though NETs are associated with poorer recurrence-free survival (RFS) and overall survival (OS), the specifics of this interaction between NETs and cancer cells are yet unknown.

Methods: The keywords "neutrophil extracellular traps and gastric cancer" were used in the GEO database for retrieval, and the GSE188741 dataset was selected to obtain the NETs-related gene. 27 NETs-related genes were screened by univariate Cox regression analysis ( < 0.05). 27 NETs-related genes were employed to identify and categorize NETs-subgroups of GC patients under the Consensus clustering analysis. 808 GC patients in TCGA-STAD combined with GES84437 were randomly divided into a training group ( = 403) and a test group ( = 403) at a ratio of 1:1 to validate the NETs-related signature.

Results: Based on Multivariate Cox regression and LASSO regression analysis to develop a NETs-related prognosis model. We developed a very specific nomogram to improve the NETs-clinical score's usefulness. Similarly, we also performed a great result in pan-cancer study with NETs-score. Low NETs scores were linked to higher MSI-H (microsatellite instability-high), mutation load, and immune activity. The cancer stem cell (CSC) index and chemotherapeutic treatment sensitivity were also connected to the NET score. Our comprehensive analysis of NETs in GC suggests that NETs have a role in the tumor microenvironment, clinicopathological features, and prognosis.

Discussion: The NETs-score risk model provides a basis for better prognosis and therapy outcomes in GC patients.

Citing Articles

Construction of a novel disulfidptosis and cuproptosis-related lncRNA signature for predicting the clinical outcome and immune response in stomach adenocarcinoma.

Qu C, Yan X, Tang F, Li Y Discov Oncol. 2025; 16(1):230.

PMID: 39992487 PMC: 11850681. DOI: 10.1007/s12672-025-01969-7.


Neutrophil extracellular traps in homeostasis and disease.

Wang H, Kim S, Lei Y, Wang S, Wang H, Huang H Signal Transduct Target Ther. 2024; 9(1):235.

PMID: 39300084 PMC: 11415080. DOI: 10.1038/s41392-024-01933-x.


Neutrophil extracellular trap-associated risk index for predicting outcomes and response to Wnt signaling inhibitors in triple-negative breast cancer.

Huang Z, Wang J, Sun B, Qi M, Gao S, Liu H Sci Rep. 2024; 14(1):4232.

PMID: 38379084 PMC: 10879157. DOI: 10.1038/s41598-024-54888-y.


Integrated analysis of NET-DNA receptor CCDC25 in malignant tumors: Pan-cancer analysis.

Cheng X, Yin X, Song J Health Sci Rep. 2023; 6(10):e1621.

PMID: 37841944 PMC: 10568976. DOI: 10.1002/hsr2.1621.

References
1.
Ossendorp F, Mengede E, Camps M, Filius R, Melief C . Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med. 1998; 187(5):693-702. PMC: 2212165. DOI: 10.1084/jem.187.5.693. View

2.
Cedervall J, Hamidi A, Olsson A . Platelets, NETs and cancer. Thromb Res. 2018; 164 Suppl 1:S148-S152. DOI: 10.1016/j.thromres.2018.01.049. View

3.
Jardim D, Goodman A, Gagliato D, Kurzrock R . The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell. 2020; 39(2):154-173. PMC: 7878292. DOI: 10.1016/j.ccell.2020.10.001. View

4.
Chung H, Arkenau H, Lee J, Rha S, Oh D, Wyrwicz L . Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. J Immunother Cancer. 2019; 7(1):30. PMC: 6362598. DOI: 10.1186/s40425-019-0508-1. View

5.
Bajou K, Peng H, Laug W, Maillard C, Noel A, Foidart J . Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis. Cancer Cell. 2008; 14(4):324-34. PMC: 2630529. DOI: 10.1016/j.ccr.2008.08.012. View